INVESTORS Marina Biotech up Thinly traded nano cap Marina Biotech (MRNA+10.6%) perks up after the company announced that it has out-licensed its SMARTICLES platform for the delivery of antisense DNA therapeutics to Oncotelic, a first for the company.
Marina Biotech up
Under the terms of the deal, Oncotelic will invest $250K in Marina via the purchase of common stock at $0.51/share. Subject to conditions, Marina may receive a commercial license fee via the sale of $500K of common shares to Oncotelic, in addition to sales-based milestones. Total potential sales milestones are capped at $90M. Additional financial terms are not disclosed.